

CLAIMS

1. A compound selected from (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable carrier.
3. Use of the compound of claim 1, in the manufacture of a medicament for the treatment of leukemia.
4. The use of claim 3, wherein at least one other anti-cancer agent is to be administered with the medicament either simultaneously or sequentially to a subject in need thereof.
5. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 98%.
6. The use of claim 3, wherein the leukemia is chronic lymphocytic leukemia (CLL).
7. The use of claim 3, wherein the leukemia is acute lymphocytic leukemia.
8. The use of claim 3, wherein the leukemia is acute myelocytic leukemia (AML).
9. The use of claim 3, wherein the leukemia is promyelocytic leukemia.
10. The use of claim 3, wherein the leukemia is chronic myelogenous leukemia.
11. (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one.
12. The compound of claim 11, wherein the compound has an enantiomeric excess of at least 98%.
13. A pharmaceutical composition comprising a compound of claim 11 and at least one pharmaceutically acceptable carrier.
14. Use of the compound of claim 11 in the manufacture of a medicament for the treatment of leukemia.
15. The use of claim 14, wherein at least one other anti-cancer agent is to be administered with the medicament either simultaneously or sequentially to a subject in need thereof.
16. The use of claim 14, wherein the leukemia is chronic lymphocytic leukemia (CLL).
17. The use of claim 14, wherein the leukemia is acute lymphocytic leukemia.
18. The use of claim 14, wherein the leukemia is acute myelocytic leukemia (AML).

19. The use of claim 14, wherein the leukemia is promyelocytic leukemia.
20. The use of claim 14, wherein the leukemia is chronic myelogenous leukemia.
21. A compound or pharmaceutically acceptable salt of claim 1 for use as a medicament.
22. A compound of claim 11 for use as a medicament.